Literature DB >> 21684324

Genetically engineered mouse models of diffuse gliomas.

Ralf S Schmid1, Mark Vitucci, C Ryan Miller.   

Abstract

Over the last decade, genetically engineered mouse models have been extensively used to dissect the genetic requirements for neoplastic initiation and progression of diffuse gliomas. While these models faithfully recapitulate the histopathological features of human gliomas, comparative genomic analyses are increasingly being utilized to comprehensively assess their fidelity to recently identified molecular subtypes of these tumors. Future progress with these models will rely on incorporating insights not only from oncogenomics studies of cancer, but also from the developmental neuroscience and stem cell biology fields to design accurate and experimentally tractable models for use in translational cancer research, particularly for experimental therapeutics studies of molecularly defined subtypes of gliomas.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21684324     DOI: 10.1016/j.brainresbull.2011.06.002

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  14 in total

1.  CEREBRAL ORGANOIDS AS A MODEL FOR GLIOBLASTOMA MULTIFORME.

Authors:  Nathaniel Silvia; Guohao Dai
Journal:  Curr Opin Biomed Eng       Date:  2020-03-25

2.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.

Authors:  Robert S McNeill; Ralf S Schmid; Ryan E Bash; Mark Vitucci; Kristen K White; Andrea M Werneke; Brian H Constance; Byron Huff; C Ryan Miller
Journal:  J Vis Exp       Date:  2014-08-12       Impact factor: 1.355

Review 3.  Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells.

Authors:  Shreyas S Rao; John J Lannutti; Mariano S Viapiano; Atom Sarkar; Jessica O Winter
Journal:  Tissue Eng Part B Rev       Date:  2013-10-30       Impact factor: 6.389

Review 4.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

5.  Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.

Authors:  Mark Vitucci; Natalie O Karpinich; Ryan E Bash; Andrea M Werneke; Ralf S Schmid; Kristen K White; Robert S McNeill; Byron Huff; Sophie Wang; Terry Van Dyke; C Ryan Miller
Journal:  Neuro Oncol       Date:  2013-06-27       Impact factor: 12.300

Review 6.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

7.  Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models.

Authors:  David M Irvin; Robert S McNeill; Ryan E Bash; C Ryan Miller
Journal:  Brain Pathol       Date:  2016-04-13       Impact factor: 6.508

8.  Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.

Authors:  Ralf S Schmid; Jeremy M Simon; Mark Vitucci; Robert S McNeill; Ryan E Bash; Andrea M Werneke; Lauren Huey; Kristen K White; Matthew G Ewend; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2016-01-28       Impact factor: 12.300

9.  Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.

Authors:  Mark Vitucci; David M Irvin; Robert S McNeill; Ralf S Schmid; Jeremy M Simon; Harshil D Dhruv; Marni B Siegel; Andrea M Werneke; Ryan E Bash; Seungchan Kim; Michael E Berens; C Ryan Miller
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

10.  Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

Authors:  Robert S McNeill; Demitra A Canoutas; Timothy J Stuhlmiller; Harshil D Dhruv; David M Irvin; Ryan E Bash; Steven P Angus; Laura E Herring; Jeremy M Simon; Kasey R Skinner; Juanita C Limas; Xin Chen; Ralf S Schmid; Marni B Siegel; Amanda E D Van Swearingen; Michael J Hadler; Erik P Sulman; Jann N Sarkaria; Carey K Anders; Lee M Graves; Michael E Berens; Gary L Johnson; C Ryan Miller
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.